What is Zacks Research’s Estimate for PBYI FY2025 Earnings?

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities researchers at Zacks Research increased their FY2025 earnings per share estimates for shares of Puma Biotechnology in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.28 per share for the year, up from their previous forecast of $0.26. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.06 EPS.

A number of other equities research analysts have also weighed in on the stock. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Monday, December 23rd.

Puma Biotechnology Stock Down 6.8 %

NASDAQ:PBYI opened at $3.31 on Friday. The company’s 50 day moving average is $3.06 and its two-hundred day moving average is $2.99. The company has a market cap of $162.48 million, a PE ratio of 6.90 and a beta of 1.10. Puma Biotechnology has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the previous year, the firm earned $0.12 earnings per share.

Hedge Funds Weigh In On Puma Biotechnology

Institutional investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. grew its position in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the period. Renaissance Technologies LLC grew its position in shares of Puma Biotechnology by 1.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after acquiring an additional 23,600 shares during the period. Great Point Partners LLC grew its position in shares of Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after acquiring an additional 142,916 shares during the period. American Century Companies Inc. increased its stake in shares of Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after purchasing an additional 366,653 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Puma Biotechnology by 6.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock worth $1,975,000 after purchasing an additional 37,684 shares during the period. 61.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the sale, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is owned by corporate insiders.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.